CHIMERNA THERAPEUTICS, INC.
New York, NY · Biotech · Private
Kits for high-yield circular RNA synthesis, purification, and labeling using proprietary Tornado technology and aptamer-based purification
- Grants
- $4.9M
- 12 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Using highly expressed circular RNAs to substantially enhance protein expression yields in mammalian cells | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Using highly expressed circular RNAs to substantially enhance protein expression yields in mammalian cells | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Circular RNA as a platform for genome-wide microRNA sponge libraries | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Circular mimics of Iron-response elements to inhibit ferroptosis | $433,356 | |
| Federal grant | Department of Health and Human Services · Phase I · Circular RNA aptamers to regulate iron homeostasis in iron overload disorders | $255,236 | |
| Federal grant | Department of Health and Human Services · Phase II · Next-generation RNA synthesis and labeling kits | $586,018 | |
| Federal grant | Department of Health and Human Services · Phase II · Next-generation RNA synthesis and labeling kits | $1,187,016 | |
| Federal grant | Department of Health and Human Services · Phase I · A Novel TDP-43-Targeting Circular RNA to Treat Amyotrophic Lateral Sclerosis (ALS) | $256,158 | |
| Federal grant | Department of Health and Human Services · Phase II · Next-generation RNA synthesis and labeling kits | $600,998 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of circRNA manufacturing platform in yeast | $297,608 | |
| Federal grant | Department of Health and Human Services · Phase II · Next-generation RNA synthesis and labeling kits | $311,060 | |
| Federal grant | Department of Health and Human Services · Phase I · Synthetic biology approaches for bio-orthogonal labeling of circular RNAs | $302,605 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1376 | HELIXOMER, INC. | — | — |
| 1377 | Vcreate, Inc. | — | — |
| 1378 | YASO THERAPEUTICS INCORPORATED | — | — |
| 1379 | CHIMERNA THERAPEUTICS, INC. | — | — |
| 1380 | Monopar Therapeutics | — | $2.1M |
| 1381 | INFLAMED, INC. | — | — |
| 1382 | XPOSE THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.